[CAS NO. 16673-34-0] NLRP3-IN-2
PRODUCTS SPECIFICATIONS [16673-34-0]
DESCRIPTION [16673-34-0]
Overview
| MDL | MFCD00193756 |
|---|---|
| Molecular Weight | 368.84 |
| Molecular Formula | C16H17ClN2O4S |
| SMILES | O=C(NCCC1=CC=C(S(=O)(N)=O)C=C1)C2=CC(Cl)=CC=C2OC |
Summary
In Vivo
NLRP3-IN-2 is well tolerated with no effects on the glucose levels in vivo
[1]
.
NLRP3-IN-2 (100 mg/kg) treatment in a model of AMI due to ischemia+reperfusion significantly inhibits the activity of inflammasome (caspase-1) in the heart by 90% (P<0.01) and reduced infarct size, measured at pathology (by >40%, P<0.01) and with troponin I levels (by >70%, P<0.01)
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Experimental acute myocardial infarction (AMI) model in mice [1] . |
| Dosage: | 100 mg/kg. |
| Administration: | Intraperitoneal administration 30 minutes prior to surgery, then every 6 hours for 3 additional doses. |
| Result: |
Led to a significant >90% reduction in caspase-1 activity (reflective of the formation of an active inflammasome) in the heart tissue measured 24 hours after ischemia.
Led to a significant reduction in the infarct size measured with TTC (>40% reduction) or troponin I levels (>70% reduction) when compared with vehicle alone. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 125 mg/mL ( 338.90 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.7112 mL | 13.5560 mL | 27.1120 mL |
| 5 mM | 0.5422 mL | 2.7112 mL | 5.4224 mL |
| 10 mM | 0.2711 mL | 1.3556 mL | 2.7112 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.64 mM); Clear solution
Synonyms